At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
MK-1496 +1 moredrug
Likely dose
MK-1496 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Dose Escalation Study of MK1496 in Patients With Advanced Solid Tumor
In Brief
A Phase 1 clinical trial evaluating MK-1496 for Neoplasms and Malignant. Completed, enrolled 27 participants.
Detailed Summary
This study determines recommended clinical dose, to evaluate the safety, tolerability and pharmacokinetics of MK-1496 in patients with locally advanced and/or metastatic solid tumors who have failed standard therapy or for whom no standard therapy exists, in two dosing schedules in Japan.
Study Details
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionNov 2010
Study CompletionJan 2011
TodayJul 2026
First PostedApr 14, 2009
Enrollment StartApr 1, 2009
Primary CompletionNov 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.2 years ago
Interventions
MK-1496drug
MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
MK-1496drug
MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle